Scholarlink

Abstract <p>In recent years, there has been a significant increase in reported cases of pulmonary thromboembolism associated with <i>Mycoplasma pneumoniae</i> pneumonia in pediatric patients, and its standardized treatment and effective prevention have increasingly attracted clinical attention. This article reviews the latest treatment approach for pulmonary thromboembolism complicated by <i>Mycoplasma pneumoniae</i> pneumonia in children, including anticoagulant therapy, systemic thrombolytic therapy, interventional therapy, and surgical therapy. Meanwhile, progress in research on the risk factors of this condition is also reviewed, aiming to provide new directions for future preventive studies.</p> Impact <p><UnorderedList Mark="Bullet"> <ItemContent> <p>While several reviews have addressed the clinical characteristics of pulmonary thromboembolism (PTE) associated with <i>Mycoplasma Pneumoniae</i> pneumonia (MPP) in pediatric patients, there remains a lack of comprehensive syntheses focusing specifically on treatment and prevention. This review provides an integrated analysis of the latest evidence on treatment strategies over the past 5 years, facilitating informed clinical decision-making. Moreover, this review is the first to systematically map the studies on the risk factors of PTE induced by MPP, directly informing the directions of future preventive studies.</p> </ItemContent> </UnorderedList></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Advances in treatment and prevention of pulmonary thromboembolism associated with Mycoplasma pneumoniae pneumonia in children

  • 期刊论文

  • 发表日期：

    2026年1月26日

查看全文
  • Yang Hu,
  • Hui Ma,
  • Renzheng Guan

摘要

Abstract

In recent years, there has been a significant increase in reported cases of pulmonary thromboembolism associated with Mycoplasma pneumoniae pneumonia in pediatric patients, and its standardized treatment and effective prevention have increasingly attracted clinical attention. This article reviews the latest treatment approach for pulmonary thromboembolism complicated by Mycoplasma pneumoniae pneumonia in children, including anticoagulant therapy, systemic thrombolytic therapy, interventional therapy, and surgical therapy. Meanwhile, progress in research on the risk factors of this condition is also reviewed, aiming to provide new directions for future preventive studies.

Impact

While several reviews have addressed the clinical characteristics of pulmonary thromboembolism (PTE) associated with Mycoplasma Pneumoniae pneumonia (MPP) in pediatric patients, there remains a lack of comprehensive syntheses focusing specifically on treatment and prevention. This review provides an integrated analysis of the latest evidence on treatment strategies over the past 5 years, facilitating informed clinical decision-making. Moreover, this review is the first to systematically map the studies on the risk factors of PTE induced by MPP, directly informing the directions of future preventive studies.